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S U M M A R Y
Visceral leishmaniasis (VL) is an opportunistic infection of HIV-infected people in several endemic
countries, and the management of this co-infection poses numerous challenges. We describe a patient
with HIV infection and visceral leishmaniasis who failed to respond to miltefosine monotherapy and
subsequently relapsed following two further different regimens of liposomal amphotericin B. He was
then successfully treated with a combination of 30 mg/kg liposomal amphotericin B and 14 days of
100 mg/day oral miltefosine.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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471. Introduction
Leishmaniasis and HIV co-infection has gained clinical impor-
tance in several countries where both infections are endemic. The
host defense against leishmaniasis in general, and Leishmania
donovani in particular, is T-cell-dependent. Accordingly, patients
with HIV infection are not only more susceptible to leishmaniasis,
but also pose signiﬁcant diagnostic as well as therapeutic
challenges. The clinical presentation in this group of patients
may not be speciﬁc, whilst therapeutic failure and relapse are more
common in co-infection. Thus there are serious implications with
respect to visceral leishmaniasis (VL) elimination strategies in
areas where the disease burden of HIV and VL overlap.
Single-dose 10 mg/kg liposomal amphotericin B is currently the
World Health Organization (WHO) recommended ﬁrst-line
treatment for VL in the Indian sub-continent.1 However, its
efﬁcacy in HIV co-infected patients has not been documented and
there are neither established guidelines nor randomized controlled
trials to guide decision-making in such patients. Furthermore, high
relapse rates and difﬁculty in eradication of Leishmania amongst
HIV-infected patients are well described, with limited evidence48
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creativecommons.org/licenses/by-nc-nd/3.0/).available regarding the best treatment strategies.2 In this case
report we describe the failure of three monotherapies in such a
patient, with subsequent successful treatment using high-dose
combination therapy.
2. Case report
A 43-year-old male from Jharkhand (a state in eastern India
endemic for VL) presented to a local hospital with a 6-month
history of low-grade fever and malaise associated with anorexia
and weight loss. He was diagnosed with both HIV-1 infection based
on serial serology testing and visceral leishmaniasis based on rK-39
serology, and was commenced on a 28-day course of oral
miltefosine 100 mg/day in two divided doses, as per the Indian
national guidelines for the treatment of VL. He was not started on
antiretroviral therapy (ART) at that stage.
Within 3 months of completing the treatment he presented to
the Christian Medical College in Vellore with recurrence of fever,
fatigue, and weight loss. Physical examination demonstrated pallor
and an enlarged liver and spleen, 5 cm and 8 cm below the costal
margin, respectively. Laboratory evaluation revealed hemoglobin
(Hb) of 8.2 g/dl, total white blood cell count of 8.2  109/l Q, platelets
of 86  109/l, and a CD4 count of 127 cells/ml. Bone marrow
aspiration conﬁrmed L. donovani. The patient was treated for VLvisceral leishmaniasis in a patient with HIV in India: a treatment
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IJID 1933 1–3ing a single dose of 10 mg/kg intravenous liposomal amphoteri-
n B (AmBisome, Gilead, USA). This regimen was lower than the
tal dose of 40 mg/kg recommended in 2010 by the WHO for HIV–
 co-infection, which is based primarily on experience of
ishmania infantum and HIV co-infection in Europe. The 10 mg/
 single-dose regimen has been shown to be highly effective in
e Indian context, albeit in immunocompetent patients.3 The
tient was commenced on tenofovir, emtricitabine, and efavirenz
r HIV, with co-trimoxazole prophylaxis. He responded well and
as discharged as initial cure following the treatment.
At the 3-month follow-up, although afebrile, he was found to
ve increased splenomegaly despite reporting full compliance
ith ART. A repeat bone marrow examination again demonstrated
donovani bodies, and the CD4 count was found to be 121 cells/ml.
 was therefore treated with a generic lipid formulation of
photericin B (Fungisome; Lifecare Innovations, India) at a
sage of 2 mg/kg for 2 weeks, receiving a cumulative dose of
 mg/kg, to which he again appeared to respond well and was
scharged again as an initial cure. This regimen was chosen as an
ternative to AmBisome due to the ﬁnancial constraints of the
tient, and took into account the lack of published safety data and
n-inferiority studies for higher doses of this particular prepara-
n of amphotericin B for the treatment of VL compared to
Bisome.3
He presented again after 6 months with a 4-week history of
alaise and fatigue despite continued adherence to ART. On
amination he demonstrated splenomegaly 6 cm below the costal
argin, Hb of 9.9 g/dl, and a CD4 count of 77 cells/ml, with a
asma HIV viral load of 63 copies/ml. A repeat bone marrow
pirate revealed a high density of L. donovani bodies.
Considering the history of multiple relapses to amphotericin B
eparations and the initial treatment failure with miltefosine, the
tient was admitted and treated with a combination regimen of
ncurrent liposomal amphotericin B (AmBisome) in six doses of
mg/kg spread over 14 days (total dose 30 mg/kg) and oral
iltefosine 50 mg twice daily for 14 days. The treatment was well
lerated with no adverse events or deterioration in biochemical
arkers, and the patient was discharged with an initial cure. The
tient’s condition improved over the 12 months following the
al treatment, which was reﬂected in a sustained improvement in
4 counts of 316 cells/ml, 421 cells/ml, and 451 cells/ml at 3, 6,
d 12 months of follow-up, respectively. At 18 months, the
tient continued to be symptom-free with weight gain, improved
, and complete regression of hepatosplenomegaly.
 Discussion
This case demonstrates the challenges in treating HIV and
ishmania co-infection for two reasons: ﬁrst the higher rate of
lapses and second the inefﬁciency of a single drug regimen. Both
V and VL affect T-cell-mediated immunity and thus tend to act
nergistically in reducing the effectiveness of the patient’s
mune responses. Co-infections with Leishmania and HIV have
us been associated with higher relapse rates of VL, a delayed
sponse to ART, and higher HIV viral loads. These patients may
ve atypical clinical presentations of leishmaniasis and are more
ely to have false-negative results when tested for VL with
rrent standard rapid diagnostic kits.4
In 2010 the WHO expert committee recommended a single dose
 10 mg/kg liposomal amphotericin B as ﬁrst-line treatment for VL
 the Indian subcontinent.1 However, its efﬁcacy in HIV co-
fection remains untested, and indeed highlights the absence of
idence for this particular clinical scenario. Liposomal amphoteri-
n B monotherapy, 20 mg/kg, has been used relatively successfully
 the Indian setting, however far higher relapse and early mortality
tes were still seen when compared to patients not known to bePlease cite this article in press as: Patole S, et al. Multiple relapses o
challenge. Int J Infect Dis (2014), http://dx.doi.org/10.1016/j.ijid.20infected with HIV receiving the same regimen.2,5 In the Ethiopian
setting, high-dose monotherapy with liposomal amphotericin B was
associated with a 32% parasitological failure rate in HIV–VL co-
infected patients.2 In such cases, repeated treatment with mono-
therapies may potentially lead to increased resistance and treatment
failures, which has already been described with oral miltefosine in
the Indian subcontinent. Meanwhile, resistance mechanisms to
amphotericin B deoxycholate have already been described in clinical
isolates of L. donovani.
Based on the synergistic properties of liposomal amphotericin B
and miltefosine, the compassionate use of this combination has
been suggested for multiple relapses of VL in HIV–VL co-infection.4
Considering the treatment history, this patient was admitted and
treated with a concurrent combination of liposomal amphotericin
B (AmBisome) in six doses of 5 mg/kg spread over 14 days (total
dose 30 mg/kg) and oral miltefosine 50 mg twice daily for 14 days.
Lower doses of this combination have already been shown to be
safe and effective in immunocompetent patients in the Indian
context,3 and this regimen allowed the entire treatment to be
administered under close inpatient supervision without an
extended patient stay, which may have major economic con-
sequences for typical VL patients in the Indian subcontinent.
The CD4 count remained persistently low in this patient despite
rigid adherence to ART over a 9-month period, during which he
relapsed and was treated twice for VL. At the initiation of the ﬁnal
treatment round with combination therapy, his CD4 count was the
lowest it had been since ART was initiated at 77 cells/ml, with a
very low viral load. Following treatment with this combination
regimen, the patient remained relapse-free at 18 months and
sustained a CD4 count >350 cells/ml. This suggests that the
recovery of immune function that allowed ﬁnal cure of the VL was
not solely attributable to the control of HIV, but rather was in part
due to the effective treatment of VL with this combination. This in
turn may have broken the vicious cycle of synergy that HIV and VL
co-infection has on the immune and hematopoietic systems.
The importance of recognizing the special needs of co-infected
patients should not be underestimated, and region-speciﬁc
guidelines need to be developed by the appropriate national
programs to recognize the problem and assist physicians in
managing this otherwise very challenging scenario. Indeed, all
HIV patients with a history of spending signiﬁcant periods in VL
endemic areas should be screened for VL, whilst all patients
diagnosed with VL should conversely be screened for HIV.
Additionally, the use of monotherapy in those patients at high
risk of relapse should be reconsidered.
In conclusion, this instructive case suggests that mono-
therapies with low-dose liposomal amphotericin B, lipid
complex amphotericin B, and 28 days of miltefosine may result
in treatment failure in HIV–VL co-infected patients, especially in
those with low CD4 counts. Combination therapy with liposomal
amphotericin B (30 mg/kg) and miltefosine (100 mg per day for
14 days) may result in a successful outcome. In the longer term,
the appropriate management of HIV–VL co-infected patients
may have an important role in reducing the reservoir of the
parasite thus working towards the ultimate aim of disease
elimination.
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